REQUEST A DEMO
Total
USD $0.00
Search more companies

Gland Pharma International Pte. Ltd. (Singapore)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Secondary Activities: Offices of Other Holding Companies
Full name: Gland Pharma International Pte. Ltd. Profile Updated: July 18, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English Download a sample report

Primary Business Activity: wholesale of medicinal and pharmaceutical products (western) (development, manufacturing and distribution of pharma products, r&d services); Secondary Business Activity: holding companies of firms engaged in non-financial and insurance activities (includes investment and acquisition of companies)

Headquarters
50 Raffles Place #30-00 Singapore Land Tower Singapore
Singapore; Singapore; Postal Code: 048623

Contact Details: Purchase the Gland Pharma International Pte. Ltd. report to view the information.

Basic Information
Financial Auditors:
Purchase the Gland Pharma International Pte. Ltd. report to view the information.
Incorporation Date:
March 10, 2021
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Company Secretary
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Gland Pharma International Pte. Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency SGD. Absolute financial data is included in the purchased report.
Net sales revenue
-38.74%
Total operating revenue
-38.74%
Net Profit (Loss) for the Period
-24.9%
Total assets
14.79%
Total equity
16.87%
Net Profit Margin
3.34%
Return on Equity (ROE)
-0.55%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?